Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Streptococcus pneumoniae type 19A capsular polysaccharide antigen
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
Streptococcus pneumoniae type 19a capsular polysaccharide antigen is a highly purified component derived from the capsule of Streptococcus pneumoniae serotype 19A. It is used as an active immunizing agent in several pneumococcal vaccines to prevent invasive diseases such as pneumococcal pneumonia and bacteremia. The mechanism of action involves stimulating the immune system to produce antibodies against the serotype-specific capsular polysaccharides, thereby providing protection against infection by S. pneumoniae serotype 19A. This antigen is included in multivalent conjugate and polysaccharide vaccines developed for broad protection against multiple S. pneumoniae serotypes[7][8][6]. Major developers and manufacturers include Pfizer (Prevnar series), Merck (Vaxneuvance), and Wyeth Pharmaceuticals (now part of Pfizer)[6][8].
- Brand names
- Pneumovax 23Pneumovax23Pneumovax-23Prevnar 13Prevnar13Prevnar-13VaxneuvancePrevnar 20Prevnar20Prevnar-20Apexxnar
- Other names
- pneumococcal capsular polysaccharide type 19A vaccine
02
Targets
19A CPS (Streptococcus pneumoniae serotype 19A capsular polysaccharide)
Beyond the preview
Go deeper on Streptococcus pneumoniae type 19A capsular polysaccharide antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Streptococcus pneumoniae type 19A capsular polysaccharide antigen.